Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

OREX 3.95 +0.04 (1.02%)
price chart
Zacks Rating on Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) remains a strong buy in the latest set of rankings. The shares have received an average rating of 1.2 by 5 analysts.
Zacks Upgrades Orexigen Therapeutics to Hold (OREX)  Dakota Financial News
Orexigen Therapeutics Receives $14.80 Consensus Target Price from Analysts ...  sleekmoney
Why It's Lights Out for Orexigen Therapeutics, Inc.
What: Shares of Orexigen Therapeutics (NASDAQ:OREX), a biopharmaceutical company focused on developing therapies to treat obesity, saw its own valuation slim down by as much as 13% during Tuesday's trading session after it and its partner Takeda ...
Orexigen Therapeutics: A Bargain After Selloff On 'Bad News' (OREX)  Seeking Alpha
Orexigen Therapeutics (OREX) Stock Continues to Sink on Contrave Study Fallout  TheStreet.com
Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker
Orexigen Therapeutics (NASDAQ:OREX) has been the darling of the obesity drugmakers, doing something Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS (NASDAQ:VVUS) weren't able to do: keep its share price above where it was when its ...
West Coast Biotech Roundup: Orexigen, Denali, Nant, ASCO & More  Xconomy
Orexigen Therapeutics, Inc. (NASDAQ:OREX) Short Interest Update
Orexigen Therapeutics, Inc. (NASDAQ:OREX) reported a drop of 2% or 710,896 shares in its short interest. The short figure came in at 35.1% of the total floats.
Earnings of $-0.15 Expected in Q2 for Orexigen Therapeutics, Inc. (NASDAQ:OREX)  Markets Daily
Stock Update - Orexigen Therapeutics, Inc. (NASDAQ:OREX)  Vanguard Tribune
Why Orexigen Therapeutics, Inc. Lost a Quarter of Its Value in May
What: Shares of Orexigen Therapeutics (NASDAQ:OREX), a small-cap drug developer focused on treating obesity, slimmed down and lost 25% of its value in May, based on data from S&P Capital IQ, after announcing bad news regarding its long-term ...
Why Orexigen Therapeutics, Inc. Lost a Sixth of Its Value in April
What: Shares of Orexigen Therapeutics (NASDAQ:OREX), a biopharmaceutical company engaged in the development of therapies for chronic weight management, lost 16% in April, or a sixth of its market value according to data from S&P Capital IQ, after it ...
Orexigen Therapeutics Inc (NASDAQ:OREX) in Spotlight  Street Report
Foresite Capital Betting It All On These Four Healthcare Stocks  Insider Monkey
Why Orexigen Therapeutics, Inc. (OREX), Gap Inc. (GPS) and Rackspace Hosting ...
Orexigen185 Why Orexigen Therapeutics, Inc. (OREX), Gap Inc. (GPS The ink didn't even have a chance to fully dry on last week's encouraging first quarter earnings report from Orexigen Therapeutics before Murphy's Law kicked in and upended OREX ...
Stock's Negative Trend: Interphase (NASDAQ:INPH), Orexigen Therapeutics ...  wsnewspublishers
Orexigen (OREX) Therapeutics Stock | Can It Recover?  CNA Finance (press release)
Actavis Plc: Orexigen Therapeutics, Inc. And Takeda Pharmaceutical File ...
Orexigen Therapeutics, Inc. (NASDAQ:OREX) and its partner Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) have filed a lawsuit against Actavis Plc (NYSE:ACT) to block a generic version of a weight-loss pill sold in the market under the name ...
Takeda Pharmaceuticals and Orexigen Therapeutics File Law Suit Against ...  Pioneer News
Orexigen, Takeda file suit against Actavis to stop generic diet pill  Reuters
Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch
The launch of Orexigen Therapeutics' (NASDAQ:OREX) obesity drug Contrave was nothing to get too excited about. In the fourth quarter, which included 10 weeks of the launch, net sales of the drug were just $6.5 million, which resulted in $1.3 million in ...
Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share  Seeking Alpha (registration)
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and ...  PR Newswire (press release)
Company Shares of Orexigen Therapeutics, Inc. Drops by -7.51%
Orexigen Therapeutics, Inc. (NASDAQ:OREX) has lost 7.51% during the past week and dropped 11.79% in the last 4 weeks.